These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 32629114)

  • 1. Dalbavancin and telavancin in the treatment of infective endocarditis: a literature review.
    Lampejo T
    Int J Antimicrob Agents; 2020 Sep; 56(3):106072. PubMed ID: 32629114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.
    Zhanel GG; Calic D; Schweizer F; Zelenitsky S; Adam H; Lagacé-Wiens PR; Rubinstein E; Gin AS; Hoban DJ; Karlowsky JA
    Drugs; 2010 May; 70(7):859-86. PubMed ID: 20426497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.
    Van Bambeke F
    Drugs; 2015 Dec; 75(18):2073-95. PubMed ID: 26603874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telavancin: a novel lipoglycopeptide for serious gram-positive infections.
    Laohavaleeson S; Kuti JL; Nicolau DP
    Expert Opin Investig Drugs; 2007 Mar; 16(3):347-57. PubMed ID: 17302529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond Vancomycin: The Tail of the Lipoglycopeptides.
    Klinker KP; Borgert SJ
    Clin Ther; 2015 Dec; 37(12):2619-36. PubMed ID: 26658277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telavancin: a lipoglycopeptide antimicrobial for the treatment of complicated skin and skin structure infections caused by gram-positive bacteria in adults.
    Chang MH; Kish TD; Fung HB
    Clin Ther; 2010 Dec; 32(13):2160-85. PubMed ID: 21316534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review.
    Thomas G; Henao-Martínez AF; Franco-Paredes C; Chastain DB
    Int J Antimicrob Agents; 2020 Sep; 56(3):106069. PubMed ID: 32603683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides.
    Al Jalali V; Zeitlinger M
    Clin Pharmacokinet; 2018 Jul; 57(7):797-816. PubMed ID: 29332251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telavancin: a novel lipoglycopeptide antimicrobial agent.
    Attwood RJ; LaPlante KL
    Am J Health Syst Pharm; 2007 Nov; 64(22):2335-48. PubMed ID: 17989443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical positioning of telavancin in Europe.
    Masterton R; Cornaglia G; Courvalin P; Lode HM; Rello J; Torres A
    Int J Antimicrob Agents; 2015 Mar; 45(3):213-20. PubMed ID: 25600892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy.
    Van Bambeke F
    Curr Opin Investig Drugs; 2006 Aug; 7(8):740-9. PubMed ID: 16955686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study.
    Stryjewski ME; Chu VH; O'Riordan WD; Warren BL; Dunbar LM; Young DM; Vallée M; Fowler VG; Morganroth J; Barriere SL; Kitt MM; Corey GR;
    Antimicrob Agents Chemother; 2006 Mar; 50(3):862-7. PubMed ID: 16495243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis.
    Agarwal R; Bartsch SM; Kelly BJ; Prewitt M; Liu Y; Chen Y; Umscheid CA
    Clin Microbiol Infect; 2018 Apr; 24(4):361-368. PubMed ID: 28882727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides.
    Tran TT; Gomez Villegas S; Aitken SL; Butler-Wu SM; Soriano A; Werth BJ; Munita JM
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0261420. PubMed ID: 35475634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dalbavancin as sequential therapy for infective endocarditis due to Gram-positive organisms: a review.
    Fazili T; Bansal E; Garner D; Gomez M; Stornelli N
    Int J Antimicrob Agents; 2023 Apr; 61(4):106749. PubMed ID: 36758775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of complicated infective endocarditis due to Enterococcus faecium in a patient with substance use disorder using oritavancin as sequential maintenance therapy.
    Giuliano G; Benedetti S; Sambo M; Pierguidi F; Tumbarello M
    Clin Microbiol Infect; 2024 Apr; 30(4):556-557. PubMed ID: 38253314
    [No Abstract]   [Full Text] [Related]  

  • 18. Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres.
    Sader HS; Mendes RE; Pfaller MA; Flamm RK
    J Antimicrob Chemother; 2019 May; 74(5):1306-1310. PubMed ID: 30753485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics, pharmacokinetics and clinical efficacy of telavancin in the treatment of pneumonia.
    Adamantia L; Antoni T
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):803-12. PubMed ID: 27158752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections.
    Zhanel GG; Trapp S; Gin AS; DeCorby M; Lagacé-Wiens PR; Rubinstein E; Hoban DJ; Karlowsky JA
    Expert Rev Anti Infect Ther; 2008 Feb; 6(1):67-81. PubMed ID: 18251665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.